Loading
OnVagus is developing a non-invasive device that stimulates the vagus nerve to prevent or reverse cancer cachexia, the weight and muscle loss that many people with cancer experience.
OnVagus, Inc., founded in 2022 according to the company, develops a non-invasive device acting on the gut-brain axis to prevent and reverse cancer-associated cachexia, without drugs, needles or surgery; the company states the device reverses weight loss, muscle atrophy, anorexia and inflammation, and these claims are the company's own. In fiscal year 2026 NCI awarded it USD 398,525 under SBIR award 1R44CA298354-01A1 for neuromodulation of the gut-brain axis in cancer cachexia.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR award (R44) 1R44CA298354-01A1: Neuromodulation of the Gut-Brain Axis to Treat Cancer-Associated Cachexia | 2026 | $399K | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/